No Data
No Data
Does Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) Deserve A Spot On Your Watchlist?
Declining Stock and Solid Fundamentals: Is The Market Wrong About Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760)?
Guosen Securities: After the centralized procurement of IVD, the industry landscape has changed, and the assembly line has become a battleground.
In the environment of centralized procurement, having TLA products with low cost and high quality will become the core competitiveness of IVD companies.
Shenzhen Mindray Bio-Medical Electronics (300760.SZ): By the end of this year, the company will launch the industry's first critical care decision support system based on AI big model technology.
In the clinical perspective, a new parameter or new technology of a medical monitor or anesthesia machine is no longer attractive enough to replace the existing equipment. However, with the integration of IT+AI, more accurate diagnosis and treatment plans, more efficient work efficiency, and more attentive patient care will impress clinical users and decision makers more effectively. At the end of this year, the company will also release the industry's first intensive care decision support system based on AI big model technology, with the goal of becoming an intelligent assistant for intensive care medical staff, and subsequent enhancements through continuous data.
Research Reports Uncover Gold | Guosen Securities: Maintains shenzhen mindray bio-medical electronics' "Outperform" rating, outstanding performance in the in vitro diagnostics business.
Guosen Securities research reports pointed out that Mindray Bio-Medical Electronics (300760.SZ) achieved revenue of 11.16 billion yuan (+10.4%) in the second quarter, with a net income of 4.4 billion yuan (+13.7%) attributable to the parent company. After excluding the impact of exchange gains and losses, the growth rate was 24%. In the first half of 2024, the growth was driven by the in vitro diagnostic business, and the ultrasound business broke through the high-end market. The in vitro diagnostic business achieved a revenue of 7.658 billion yuan (+28.16%) in the first half of the year, with the chemical luminescence business growing by more than 30%. The domestic in vitro diagnostic business grew by more than 25% in the first half of the year, with the domestic hematology business growing by more than 30%. Medical imaging business
Results: Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts